Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06336356 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate Cortisol Reserve in Response to Adrenocorticotropic Hormone (ACTH) Stimulation Test Following Baxdrostat Treatment Compared to Placebo in Participants With Uncontrolled Hypertension
A Phase 2 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 2
- Development phase
- 48
- Enrollment target
NCT06336356 is a Phase 2 study that has completed, run by AstraZeneca. The registered enrollment target is 48 participants.
The verdict
NCT06336356, a Phase 2 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 48 participants
- Enrollment target
Study Summary
The main purpose of this study is to assess the serum free cortisol response after ACTH stimulation test at baseline and at Week 8 in participants with uncontrolled hypertension.
Interventions
- DRUG Placebo
- DRUG Baxdrostat
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 48 participants |
| Start Date | 2024-06-10 |
| Est. Completion | 2024-12-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06336356
The ClinicalTrials.gov registry entry for NCT06336356 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 48 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT06336356 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06336356 about?
NCT06336356 is a clinical study titled "A Study to Evaluate Cortisol Reserve in Response to Adrenocorticotropic Hormone (ACTH) Stimulation Test Following Baxdrostat Treatment Compared to Placebo in Participants With Uncontrolled Hypertension". The main purpose of this study is to assess the serum free cortisol response after ACTH stimulation test at baseline and at Week 8 in participants with uncontrolled hypertension.
What is the current status of trial NCT06336356?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 48 participants. The study started on 2024-06-10. Estimated completion is 2024-12-04.
What interventions are being tested in trial NCT06336356?
The interventions under investigation include: Placebo (DRUG), Baxdrostat (DRUG).
Who is sponsoring clinical trial NCT06336356?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.